Holen Sie sich die Stockscreener-App
14.66
1.95%
0.28
Handel nachbörslich:
14.34
-0.32
-2.18%
Schlusskurs vom Vortag:
$14.38
Offen:
$14.49
24-Stunden-Volumen:
1.02M
Relative Volume:
0.69
Marktkapitalisierung:
$2.08B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-42.76M
KGV:
-45.70
EPS:
-0.3208
Netto-Cashflow:
$-42.09M
1W Leistung:
+5.92%
1M Leistung:
+22.78%
6M Leistung:
+37.78%
1J Leistung:
+112.46%
1-Tages-Spanne:
$14.28
$14.78
1-Wochen-Bereich:
$13.11
$14.78
52-Wochen-Spanne:
$5.3801
$16.12
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
14.66 | 2.04B | 0 | -42.76M | -42.09M | -0.3208 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-08-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Trevi Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Trevi Therapeutics Q1 2026 Earnings Call Transcript - Benzinga
Earnings call transcript: Trevi Therapeutics Q1 2026 highlights cash boost and clinical progress - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Trevi Therapeutics (NASDAQ: TRVI) raises $162M, funds cough trials - Stock Titan
Trevi Therapeutics (NASDAQ: TRVI) widens Q1 loss and raises $173M - Stock Titan
Fresh $162M gives Trevi runway into 2030 ahead of Phase 3 cough trials - Stock Titan
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire
MSN Money - MSN
Pictet Asset Management Holding SA Purchases 1,520,754 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
Trevi Therapeutics, Inc. Announces Oral Nalbuphine Extended-Release Clinical Trial Results And Presentations - marketscreener.com
Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Trevi Therapeutics (TRVI.US) is scheduled to release its earnings report after the market closes on May 5. - Moomoo
TRVI stock’s five-day rally pushes it to an all-time high – here’s what’s happening - MSN
Trevi Therapeutics Closes $173 Million Public Offering - Global Legal Chronicle
Clinical-stage biotech Trevi sets May 5 webcast for Q1 results - Stock Titan
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 - marketscreener.com
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - Quantisnow
Trevi Therapeutics launches $150M public stock offering - MSN
Peregrine Capital Management LLC Lowers Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics to Participate in Upcoming May Events - The Manila Times
New Haven-based Trevi Therapeutics raises $173M in public offering - Hartford Business Journal
Trevi lines up a May 7 investor day and May 12 conference webcast - Stock Titan
Trevi Therapeutics (TRVI) Stock: Is It Holding Support | Q4 2025: Earnings Beat EstimatesEquity Raise - Cổng thông tin điện tử Tỉnh Sơn La
Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative? - Yahoo Finance
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Trevi Therapeutics (NASDAQ: TRVI) asks holders to OK share, equity plan boosts - Stock Titan
[ARS] Trevi Therapeutics, Inc. SEC Filing - Stock Titan
Leerink raises Trevi Therapeutics stock price target on ILD outlook By Investing.com - Investing.com Canada
Trevi Therapeutics Closes $173 Million Share Offering - marketscreener.com
Trevi Therapeutics announces closing of $173 million underwritten offering - marketscreener.com
Trevi Therapeutics Announces Closing Of $173 Million Underwritten Offering - TradingView
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - ChartMill
Can Trevi Therapeutics Address The Big Unmet Need In Chronic Cough? - RTTNews
Trevi Therapeutics (TRVI) Stock: Slowing Down? (Breakout Watch) 2026-04-18Trending Picks - Cổng thông tin điện tử tỉnh Tây Ninh
What's Going On With Trevi Therapeutics Stock? - Sahm
Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
TRVI Maintains Buy Rating by D. Boral Capital -- Price Target Un - GuruFocus
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):